FDA Approves Weekly Insulin Onswik for Type 2 Diabetes, Advises Against Use in Type 1 Patients

The FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly long-acting insulin, for adults with type 2 diabetes as an adjunct to diet and exercise. The agency’s 2026 novel drug approvals list records the approval date as September 23, with Eli Lilly announcing it the following day. Per the label, Onswik is not recommended for individuals with type 1 diabetes due to an elevated risk of severe hypoglycemia, and its safety and efficacy have not been established in pediatric populations.

For adults accustomed to daily basal insulin, the primary advantage of Onswik is convenience rather than superior efficacy. Lilly’s clinical trials demonstrated that Onswik lowers blood sugar roughly as effectively as daily insulin, not more. Onswik represents the second weekly basal insulin approved in the United States, succeeding Novo Nordisk’s Awiqli, which was approved in March.

As Effective as Daily Insulin, Not Proven Better

The approval is supported by four Phase 3 QWINT trials encompassing over 3,400 adults with type 2 diabetes, according to Lilly’s announcement. Across all trials, Onswik achieved its primary goal of noninferior A1C reduction compared to daily insulin glargine or insulin degludec. Noninferiority indicates the drug was not significantly worse, staying within a preset margin of 0.4 percentage points. The outcomes were closely matched. In QWINT-1, A1C levels dropped 1.19 points with Onswik versus 1.16 points with glargine over 52 weeks, while QWINT-4 saw drops of 1.01 and 1.00 points, respectively, as reported by HCPLive. Moderate-to-severe low blood sugar occurred less frequently with Onswik in QWINT-1, though results were not significantly different in the other three trials. In QWINT-3, serious adverse events affected 16% of Onswik users compared to 11% of degludec users, with cardiovascular-related issues being the most common in both groups. In QWINT-1, insulin-naive patients required a median of two dose adjustments on Onswik compared to eight on glargine—a significant factor for those who find frequent adjustments burdensome. These patients began at 100 units per week, with fixed increases to 150, 250, and 400 units at four-week intervals as needed. In QWINT-2, time spent within the target glucose range was 64.3% with Onswik and 61.2% with degludec. These randomized, open-label trials meant both patients and physicians knew which insulin was being administered. Sponsored by Lilly, QWINT-1 and QWINT-2 were published in The New England Journal of Medicine, while QWINT-3 and QWINT-4 appeared in The Lancet. While the trials showed comparable blood sugar control, they did not prove Onswik is safer or more effective than daily insulin.

Type 1 Limits, Side Effects, and Dosing Cautions

The type 1 restriction is the most critical caveat. Individuals with type 1 diabetes produce little to no insulin, meaning dosing errors and hypoglycemia can escalate rapidly; the label specifically cites an increased risk of severe hypoglycemia for this demographic. Common side effects include hypoglycemia, allergic and injection-site reactions, skin thickening or pitting at the injection point, itching, rash, hand and foot swelling, and weight gain. The prescribing information also warns of severe risks, such as serious allergic reactions, low potassium levels, and heart failure when combined with thiazolidinediones (TZDs). Symptoms of low blood sugar include shakiness, sweating, dizziness, confusion, blurred vision, rapid heartbeat, and hunger. Dosing differs from daily insulin, and errors remain a genuine concern. The KwikPen comes in two concentrated strengths delivering up to 400 or 800 units per injection. Lilly warns patients against drawing the insulin from the pen with a syringe and to verify the pen label before each dose to prevent mix-ups. Blind or visually impaired patients should not use the pen without assistance from a trained individual. Onswik must not be used in an insulin pump or injected into a vein or muscle. The prescribing information advises against its use during pregnancy or breastfeeding, urging affected individuals to consult their clinician. Lilly also recommends avoiding driving or operating heavy machinery until the patient understands how the insulin affects them. Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, stated, “delays in initiating treatment and the burden of daily injections can have a real impact on patients’ day-to-day experience managing type 2 diabetes.” A weekly regimen equates to roughly 52 injections per year instead of approximately 365. If a dose is missed, it should be taken as soon as possible within four days, followed by the regular weekly schedule, and patients must never alter or switch insulin without a clinician’s guidance.

Cost, Availability, and Questions to Ask a Clinician

Lilly states the Onswik KwikPen will reach U.S. pharmacies in the coming months. The company has not released a price, and insurers have yet to indicate whether or how they will cover it. Previous reports noted that the first weekly insulin reached 70,000 U.S. pharmacies after its launch, suggesting competition could eventually influence pricing. Patients who struggle with daily injections should inquire whether a weekly insulin is appropriate for them. Valuable questions include how to recognize and treat low blood sugar, what to do following a missed dose, and whether kidney or liver issues, heart failure, pregnancy plans, or TZD use alter the decision. Severe symptoms like confusion, fainting, or seizures resulting from low blood sugar require immediate emergency care. Onswik has also received regulatory approval in the European Union, Mexico, and Japan. Real-world safety data, pricing, and insurance determinations will ultimately dictate its broader adoption.

Key Questions Answered

What did the FDA approve?

Onswik, a once-weekly basal insulin for adults with type 2 diabetes, used alongside diet and exercise.

Can people with type 1 diabetes use it?

The label indicates Onswik is not recommended for people with type 1 diabetes due to an increased risk of severe low blood sugar.

Is it better than daily insulin?

The trials demonstrated that it lowered A1C approximately as well as daily insulin, not better. Rates of moderate-to-severe low blood sugar were similar in three of the four trials and lower with Onswik in one.

What are the main side effects?

Low blood sugar, allergic and injection-site reactions, skin changes at the injection site, itching, rash, swelling of the hands and feet, and weight gain.

When will it be available and how much will it cost?

Lilly states it will be available in the coming months. A price has not been announced, and insurance coverage is not yet known.

Source link